These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

275 related articles for article (PubMed ID: 32279388)

  • 1. Activator of thyroid and retinoid receptor increases sorafenib resistance in hepatocellular carcinoma by facilitating the Warburg effect.
    Ma L; Liu W; Xu A; Ji Q; Ma Y; Tai Y; Wang Y; Shen C; Liu Y; Wang T; Han J; Zhao C
    Cancer Sci; 2020 Jun; 111(6):2028-2040. PubMed ID: 32279388
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Microbiota-derived SSL6 enhances the sensitivity of hepatocellular carcinoma to sorafenib by down-regulating glycolysis.
    Zhang X; Wu L; Xu Y; Yu H; Chen Y; Zhao H; Lei J; Zhou Y; Zhang J; Wang J; Peng J; Jiang L; Sheng H; Li Y
    Cancer Lett; 2020 Jul; 481():32-44. PubMed ID: 32246956
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Simvastatin re-sensitizes hepatocellular carcinoma cells to sorafenib by inhibiting HIF-1α/PPAR-γ/PKM2-mediated glycolysis.
    Feng J; Dai W; Mao Y; Wu L; Li J; Chen K; Yu Q; Kong R; Li S; Zhang J; Ji J; Wu J; Mo W; Xu X; Guo C
    J Exp Clin Cancer Res; 2020 Jan; 39(1):24. PubMed ID: 32000827
    [TBL] [Abstract][Full Text] [Related]  

  • 4. EGFR signaling confers resistance to BET inhibition in hepatocellular carcinoma through stabilizing oncogenic MYC.
    Yin Y; Sun M; Zhan X; Wu C; Geng P; Sun X; Wu Y; Zhang S; Qin J; Zhuang Z; Liu Y
    J Exp Clin Cancer Res; 2019 Feb; 38(1):83. PubMed ID: 30770740
    [TBL] [Abstract][Full Text] [Related]  

  • 5. SOX9 enhances sorafenib resistance through upregulating ABCG2 expression in hepatocellular carcinoma.
    Wang M; Wang Z; Zhi X; Ding W; Xiong J; Tao T; Yang Y; Zhang H; Zi X; Zhou W; Huang G
    Biomed Pharmacother; 2020 Sep; 129():110315. PubMed ID: 32554246
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CRIPTO promotes an aggressive tumour phenotype and resistance to treatment in hepatocellular carcinoma.
    Karkampouna S; van der Helm D; Gray PC; Chen L; Klima I; Grosjean J; Burgmans MC; Farina-Sarasqueta A; Snaar-Jagalska EB; Stroka DM; Terracciano L; van Hoek B; Schaapherder AF; Osanto S; Thalmann GN; Verspaget HW; Coenraad MJ; Kruithof-de Julio M
    J Pathol; 2018 Jul; 245(3):297-310. PubMed ID: 29604056
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Zinc finger protein 703 induces EMT and sorafenib resistance in hepatocellular carcinoma by transactivating CLDN4 expression.
    Wang H; Xu H; Ma F; Zhan M; Yang X; Hua S; Li W; Li Y; Lu L
    Cell Death Dis; 2020 Apr; 11(4):225. PubMed ID: 32269215
    [TBL] [Abstract][Full Text] [Related]  

  • 8. DNMT3b/OCT4 expression confers sorafenib resistance and poor prognosis of hepatocellular carcinoma through IL-6/STAT3 regulation.
    Lai SC; Su YT; Chi CC; Kuo YC; Lee KF; Wu YC; Lan PC; Yang MH; Chang TS; Huang YH
    J Exp Clin Cancer Res; 2019 Nov; 38(1):474. PubMed ID: 31771617
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The kynurenine derivative 3-HAA sensitizes hepatocellular carcinoma to sorafenib by upregulating phosphatases.
    Gan G; Shi Z; Shangguan C; Zhang J; Yuan Y; Chen L; Liu W; Li B; Meng S; Xiong W; Mi J
    Theranostics; 2021; 11(12):6006-6018. PubMed ID: 33897895
    [No Abstract]   [Full Text] [Related]  

  • 10. HIF-1α-induced RIT1 promotes liver cancer growth and metastasis and its deficiency increases sensitivity to sorafenib.
    Song Z; Liu T; Chen J; Ge C; Zhao F; Zhu M; Chen T; Cui Y; Tian H; Yao M; Li J; Li H
    Cancer Lett; 2019 Sep; 460():96-107. PubMed ID: 31247273
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Downregulation of amplified in breast cancer 1 contributes to the anti-tumor effects of sorafenib on human hepatocellular carcinoma.
    Li M; Wang W; Dan Y; Tong Z; Chen W; Qin L; Liu K; Li W; Mo P; Yu C
    Oncotarget; 2016 May; 7(20):29605-19. PubMed ID: 27105488
    [TBL] [Abstract][Full Text] [Related]  

  • 12. GPAT3 is a potential therapeutic target to overcome sorafenib resistance in hepatocellular carcinoma.
    Zhou Y; Zhao H; Ren R; Zhou M; Zhang J; Wu Z; Chen Y; Lei J; Chen Y; Yu Y; Li Y
    Theranostics; 2024; 14(9):3470-3485. PubMed ID: 38948063
    [No Abstract]   [Full Text] [Related]  

  • 13. Hypoxia-mediated sorafenib resistance can be overcome by EF24 through Von Hippel-Lindau tumor suppressor-dependent HIF-1α inhibition in hepatocellular carcinoma.
    Liang Y; Zheng T; Song R; Wang J; Yin D; Wang L; Liu H; Tian L; Fang X; Meng X; Jiang H; Liu J; Liu L
    Hepatology; 2013 May; 57(5):1847-57. PubMed ID: 23299930
    [TBL] [Abstract][Full Text] [Related]  

  • 14. SREBP-1 inhibitor Betulin enhances the antitumor effect of Sorafenib on hepatocellular carcinoma via restricting cellular glycolytic activity.
    Yin F; Feng F; Wang L; Wang X; Li Z; Cao Y
    Cell Death Dis; 2019 Sep; 10(9):672. PubMed ID: 31511501
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Genistein suppresses aerobic glycolysis and induces hepatocellular carcinoma cell death.
    Li S; Li J; Dai W; Zhang Q; Feng J; Wu L; Liu T; Yu Q; Xu S; Wang W; Lu X; Chen K; Xia Y; Lu J; Zhou Y; Fan X; Mo W; Xu L; Guo C
    Br J Cancer; 2017 Nov; 117(10):1518-1528. PubMed ID: 28926527
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Programmed Death Ligand-1 (PD-L1) Regulated by NRF-2/MicroRNA-1 Regulatory Axis Enhances Drug Resistance and Promotes Tumorigenic Properties in Sorafenib-Resistant Hepatoma Cells.
    Li D; Sun FF; Wang D; Wang T; Peng JJ; Feng JQ; Li H; Wang C; Zhou DJ; Luo H; Fu ZQ; Zhang T
    Oncol Res; 2020 Dec; 28(5):467-481. PubMed ID: 32560747
    [TBL] [Abstract][Full Text] [Related]  

  • 17. KIAA1199 promotes sorafenib tolerance and the metastasis of hepatocellular carcinoma by activating the EGF/EGFR-dependent epithelial-mesenchymal transition program.
    Xu Y; Xu H; Li M; Wu H; Guo Y; Chen J; Shan J; Chen X; Shen J; Ma Q; Liu J; Wang M; Zhao W; Hong J; Qi Y; Yao C; Zhang Q; Yang Z; Qian C; Li J
    Cancer Lett; 2019 Jul; 454():78-89. PubMed ID: 30980868
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Enhancer of zeste 2 polycomb repressive complex 2 subunit promotes sorafenib resistance of hepatocellular carcinoma though insulin-like growth factor 1 receptor.
    Hu J; Zhang J; Sun F; Qi M; Su P; Liu H; Gao L; Jiao M; Wu Z; Xiang L; Han B
    Anticancer Drugs; 2019 Aug; 30(7):e0746. PubMed ID: 31305292
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of annexin A3 blockade in sensitizing hepatocellular carcinoma to sorafenib and regorafenib.
    Tong M; Che N; Zhou L; Luk ST; Kau PW; Chai S; Ngan ES; Lo CM; Man K; Ding J; Lee TK; Ma S
    J Hepatol; 2018 Oct; 69(4):826-839. PubMed ID: 29885413
    [TBL] [Abstract][Full Text] [Related]  

  • 20. ID1-induced p16/IL6 axis activation contributes to the resistant of hepatocellular carcinoma cells to sorafenib.
    Niu LL; Cheng CL; Li MY; Yang SL; Hu BG; Chong CCN; Chan SL; Ren J; Chen GG; Lai PBS
    Cell Death Dis; 2018 Aug; 9(9):852. PubMed ID: 30154433
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.